These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26758586)

  • 1. Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.
    Stroh M; Green M; Cha E; Zhang N; Wada R; Jin J
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):485-94. PubMed ID: 26758586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
    Bria E; Cuppone F; Ciccarese M; Nisticò C; Facciolo F; Milella M; Izzo F; Terzoli E; Cognetti F; Giannarelli D
    Cancer Treat Rev; 2006 Dec; 32(8):583-7. PubMed ID: 16919884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
    Hanna N; Shepherd FA; Fossella FV; Pereira JR; De Marinis F; von Pawel J; Gatzemeier U; Tsao TC; Pless M; Muller T; Lim HL; Desch C; Szondy K; Gervais R; Shaharyar ; Manegold C; Paul S; Paoletti P; Einhorn L; Bunn PA
    J Clin Oncol; 2004 May; 22(9):1589-97. PubMed ID: 15117980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
    Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
    Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
    Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
    Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
    Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
    BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
    Li R; Sun L; Wang J; Qian J; Wang Z; Jiao X
    Pulm Pharmacol Ther; 2012 Oct; 25(5):364-70. PubMed ID: 22766314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
    Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment.
    Jin Y; Sun Y; Shi X; Zhao J; Shi L; Hong W; Yu X
    Clin Ther; 2014 Dec; 36(12):1980-1990. PubMed ID: 25256387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials.
    Zhao YL; Han S; Pu R; Shi LW
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e86-91. PubMed ID: 25818741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
    Tibaldi C; Bernardini I; Chella A; Russo F; Vasile E; Malventi M; Falcone A
    Clin Lung Cancer; 2006 May; 7(6):401-5. PubMed ID: 16800966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
    Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
    J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
    Abe T; Takeda K; Ohe Y; Kudoh S; Ichinose Y; Okamoto H; Yamamoto N; Yoshioka H; Minato K; Sawa T; Iwamoto Y; Saka H; Mizusawa J; Shibata T; Nakamura S; Ando M; Yokoyama A; Nakagawa K; Saijo N; Tamura T
    J Clin Oncol; 2015 Feb; 33(6):575-81. PubMed ID: 25584004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
    Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.
    Di Maio M; Perrone F; Chiodini P; Gallo C; Camps C; Schuette W; Quoix E; Tsai CM; Gridelli C
    J Clin Oncol; 2007 Apr; 25(11):1377-82. PubMed ID: 17416857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.